BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: See L, Lee H, Chao T, Li P, Liu J, Wu L, Chang S, Yeh Y, Kuo C, Chan Y, Lip GYH. Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis. Cardiovasc Drugs Ther 2021;35:975-86. [DOI: 10.1007/s10557-020-07108-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Magnocavallo M, Bellasi A, Mariani MV, Fusaro M, Ravera M, Paoletti E, Di Iorio B, Barbera V, Della Rocca DG, Palumbo R, Severino P, Lavalle C, Di Lullo L. Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy. J Clin Med 2020;10:E83. [PMID: 33379379 DOI: 10.3390/jcm10010083] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Wetmore JB, Weinhandl ED, Yan H, Reyes JL, Herzog CA, Roetker NS. Apixaban Dosing Patterns Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation Receiving Dialysis: A Retrospective Cohort Study. American Journal of Kidney Diseases 2022. [DOI: 10.1053/j.ajkd.2022.03.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Xu R, Wu F, Lan J, Duan P. Real-world comparison of direct-acting oral anticoagulants and vitamin K antagonists in chronic kidney disease: a systematic review and meta-analysis. Expert Rev Hematol 2021;14:493-502. [PMID: 33949923 DOI: 10.1080/17474086.2021.1920012] [Reference Citation Analysis]
4 Liao J, Kuo L, Liu C, Chen S, Chao T. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with advanced chronic kidney and liver diseases. European Heart Journal Supplements 2022;24:A11-8. [DOI: 10.1093/eurheartj/suab154] [Reference Citation Analysis]
5 Chao TF, Joung B, Takahashi Y, Lim TW, Choi EK, Chan YH, Guo Y, Sriratanasathavorn C, Oh S, Okumura K, Lip GYH. 2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. J Arrhythm 2021;37:1389-426. [PMID: 34887945 DOI: 10.1002/joa3.12652] [Reference Citation Analysis]
6 Starr JA, Pinner NA, Mannis M, Stuart MK. A Review of Direct Oral Anticoagulants in Patients With Stage 5 or End-Stage Kidney Disease. Ann Pharmacother 2021;:10600280211040093. [PMID: 34459281 DOI: 10.1177/10600280211040093] [Reference Citation Analysis]
7 Cases A, Gomez P, Broseta JJ, Perez Bernat E, Arjona Barrionuevo JD, Portolés JM, Gorriz JL. Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K Antagonists and Direct Oral Anticoagulants. A Narrative Review. Front Med (Lausanne) 2021;8:654620. [PMID: 34604247 DOI: 10.3389/fmed.2021.654620] [Reference Citation Analysis]